Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Sarilumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kevzara® (sarilumab) Approved by FDA for the Treatment of Active (pJIA)
    Kevzara® (sarilumab) Approved by FDA for the Treatment of Active (pJIA)

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2896639/0/en/Kevzara-sarilumab-Approved-by-FDA-for-the-Treatment-of-Active-Polyarticular-Juvenile-Idiopathic-Arthritis-pJIA.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share
    Sanofi Synthelabo Biologic Sarilumab Receives Approval in US
    Sanofi Synthelabo Biologic Sarilumab Receives Approval in US

    10 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761037

    FDA
    10 Jun 2024
    Share Share
    US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
    US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica

    02 Mar 2023

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/fda-regeneron-sanofi-polymyalgia-rheumatica/

    PHARMACEUTICAL TECHNOLOGY
    02 Mar 2023
    Share Share
    Kevzara Approved by FDA as First Biologic Indicated for Polymyalgia Rheumatica
    Kevzara Approved by FDA as First Biologic Indicated for Polymyalgia Rheumatica

    28 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/01/2617778/0/en/Kevzara-sarilumab-Approved-by-FDA-as-First-and-Only-Biologic-Indicated-for-Patients-with-Polymyalgia-Rheumatica.html

    GLOBENEWSWIRE
    28 Feb 2023
    Share Share
    Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
    Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022

    13 Oct 2021

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2021/2021-10-12-18-16-27-2312865

    PRESS RELEASE
    13 Oct 2021
    Share Share
    MSF demands newest COVID-19 treatment recommended by WHO accessible to all
    MSF demands newest COVID-19 treatment recommended by WHO accessible to all

    27 Sep 2021

    // EXPRESS PHARMA

    https://www.expresspharma.in/msf-demands-newest-covid-19-treatment-recommended-by-who-must-be-accessible-to-all/

    EXPRESS PHARMA
    27 Sep 2021
    Share Share